Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA® in Europe for the Treatment of Metastatic Breast Cancer Allarity Therapeutics A/S
Press release
Hørsholm, Denmark (4 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that it has enrolled the first patient in its European Phase 2 clinical trial of IXEMPRA
® (ixabepilone) for the treatment of metastatic breast cancer.
The U.S. Food and Drug Administration (FDA) approved IXEMPRA
®, a microtubulin inhibitor, in 2007 for the treatment of metastatic breast cancer. Allarity holds exclusive European option rights to IXEMPRA
® from the pharmaceutical company R-Pharm U.S., LLC, which previously acquired global rights to the drug from Bristol-Myers Squibb (BMS). Allarity has previously developed and validated a Drug Response Predictor (DRP
Embracer Group publishes Interim Report Q3, October-December 2020: Operational EBIT Increased 100% to SEK 603 Million
THIRD QUARTER, OCTOBER-DECEMBER 2020 (COMPARED TO OCTOBER-DECEMBER 2019)
> Net sales increased by 44% to SEK 2,168.1 million (1,508.5). Net sales of the Games business area increased by 62% to SEK 1,355.6 million (835.7). THQ Nordic SEK 379.8 million (333.0), Deep Silver SEK 496.9 million (466.6), Coffee Stain SEK 99.2 million (36.1), Saber Interactive SEK 307.0 million (-) and DECA Games SEK 72.7 million (-).
> Net sales of Partner Publishing/Film business area increased by 21% to SEK 812.5 million (672.9).
> EBITDA increased by 70% to SEK 878.7 million (518.4), corresponding to an EBITDA margin of 41%.
> Operational EBIT increased by 100% to SEK 603.1 million (302.1) corresponding to an Operational EBIT margin of 28% (20%).
(2)
Press Release
Hørsholm, Denmark (26 January 2021) - Allarity Therapeutics A/S ( Allarity or the Company ) today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the British variant ), at the Pathogen and Microbiome Institute at Northern Arizona University (NAU).
The virus variant was labelled Variant of Concern 202012/01 by Public Health England (PHE), an agency of the UK Department of Health & Social Care, in a publication on 21 December 2020, after it was found to have spread rapidly within the UK, and the PHE assessed that this variant has a substantially increased transmissibility compared with other Coronavirus variants. This variant has also been identified in the U.S. in several states.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Allarity Therapeutics to test activity of its PARP inhibitor, stenoparib, as a potential .
Allarity Therapeutics A/SJanuary 26, 2021 GMT
Press Release
Hørsholm, Denmark (26 January 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced plans to further test the antiviral activity of stenoparib, its PARP inhibitor, against SARS-CoV-2 lineage B.1.1.7, also known as Coronavirus Variant B117 (the “British variant”), at the Pathogen and Microbiome Institute at Northern Arizona University (NAU).
The virus variant was labelled “Variant of Concern 202012/01” by Public Health England (PHE), an agency of the UK Department of Health & Social Care, in a publication on 21 December 2020, after it was found to have spread rapidly within the UK, and the PHE assessed that this variant has a substantially increased transmissibility compared with other Coronav
2020 in Review: A Letter from Allarity s CEO wboc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wboc.com Daily Mail and Mail on Sunday newspapers.